

# Nano Sponges: Applications and a Specific Drug Delivery System

Pranjal Lokhande<sup>1</sup>, Sonali Sonawane<sup>2</sup>, Dr. Santhosh Ghule<sup>3</sup>, Srushti Bhujbal<sup>1</sup>, Yash Chaudhari<sup>1</sup>

<sup>1</sup>Department of Pharmacy, Samarth College of Pharmacy, Belhe, Pune, Maharashtra, India

<sup>2</sup>Assistant Professor, Samarth College of Pharmacy, Belhe, Pune, Maharashtra, India

<sup>3</sup>Professor, Department of Pharmacology, Samarth College of Pharmacy, Belhe, Pune, Maharashtra, India

Corresponding Author: Pranjal Lokhande, pranjal24lokhande@gmail.com

**Abstract:** Nano sponges have emerged as a promising paradigm in the realm of drug delivery systems, offering unprecedented advantages in targeted and controlled drug release. This review encapsulates the synthesis methodologies, structural features, and the myriad applications of nano sponges as a versatile platform for drug delivery. The porous nanostructure of these materials provides an ideal reservoir for encapsulating diverse therapeutic agents, facilitating precise and sustained release at specific target sites. The unique physicochemical properties of nano sponges, including their biocompatibility and tunable surface functionalities, contribute to enhanced drug stability and bioavailability. Furthermore, the ability to tailor the size and composition of nano sponges allows for customization, optimizing their performance for various therapeutic scenarios. This review comprehensively explores the applications of nano sponges in treating diverse diseases, such as cancer, infectious diseases, and inflammatory disorders, showcasing their potential to revolutionize the landscape of modern medicine. The integration of nano sponges as a targeted drug delivery system holds promise for minimizing side effects, improving patient compliance, and maximizing the therapeutic efficacy of pharmaceutical agents, marking a significant stride towards personalized and precision medicine.

**Keywords:** Nano sponges; Targeted drug delivery; Solubility enhancement; Controlled drug delivery

## REFERENCES

- [1]. Amber V, Shailendra S, Swarnalatha S. (2008). cyclodextrin based novel drug delivery systems. Journal of Inclusion phenomena and macrocyclic chemistry, 62, 23-42.
- [2]. Sinha VR, Anitha R, Ghosh S, Nanda A, Kumria R. (2005).Complexation of celecoxib with beta cyclodextrin: characterization of the interaction in solution and in solid state. Journal of Pharmaceutical Sciences, 94(3), 676- 687.
- [3]. Lala R, Thorat A, and Gargote C. (2011). Current trends in beta- cyclodextrin based drug delivery systems. International Journal of Research in Ayurvedha and pharmacy, 2(5), 1520-1526.
- [4]. Subramanian S, Singireddy A, Krishnamoorthy K, and Rajappan M. (2012). Nanosponges: a novel class of drug delivery system- review. Journal of Pharmacy and Pharmaceutical sciences, 15(1), 103- 111.
- [5]. Swaminathan S, Pastero L, Serpe L, Trotta F, Vavia P, Aquilano D, Trotta M, Zara G and Cavalli R. (2010). Cyclodextrin –based nanosponges encapsulating camptothecin: Physicochemical characterization, stability and cytotoxicity. European Journal of Pharmaceutics and Biopharmaceutics, 74 (2), 193-201.
- [6]. Ramnik S, Nitin B, Jyotsana M and Horemam SN. (2010). Characterization of cyclodextrin inclusion complexes. Review. Journal of Pharmaceutical Sciences and Technology, 2(3), 171-183.
- [7]. Rajeswari C, Alka A, Javed A and Khar RK. (2005). Cyclodextrin in the drug delivery: an update review. American Association of Pharmaceutical Scientists, 6(2), E329-E357.
- [8]. Selvamuthukumar S, Anandam S, Kannan K and Manavalan R. (2012). Nanosponge; A novel class of drug delivery system –review. Journal of Pharmacy and Pharmaceutical sciences, 15(1), 103-111.
- [9]. Shastrulagari S and Samskruthi KP. (2015). Nanosponge: novel emerging drug delivery system- a review .International Journal of Pharmaceutical Sciences and Research,6(2), 1000-12.

- [10]. Mognetti B, Barberis A, Marino S and Trotta F. (2012). In vitro enhancement of anticancer activity of paclitaxel by a cremophor free cyclodextrin-based nanosponge formulations. *Journal of Inclusion Phenomena and Macro cyclic Chemistry*, 74(1-4), 201-210.
- [11]. Tejashri G, Amrita B and Darshana J. (2013). Cyclodextrin based nanosponges for pharmaceutical use; a review. *Acta Pharma*, 63(3), 335-358.
- [12]. Boscolo B, Trotta F and Ghibaudi E. (2010). High catalytic performance of pseudomonas fluorescence lipase desorbed on a new type of cyclodextrin based nanosponges. *Journal of Molecular Catalysis B Enzymatic*, 62, 155-161
- [13]. Swaminthan S, Cavalli R, Trotaa F and Ferti (2010). In vitro release modulation and conformational stabilization of a model protein using swellablepolyamidoaminenanosponges of cyclodextrin. *Journal of Inclusion Phenomena and Macro cyclic Chemistry*, 68(1-2), 183-191.
- [14]. Rosalba M, Roberta C, Piergioorgio P, Roberto F, Leigh E and Chiara D. (2011). Antitumor activity of nanosponges –encapsulated camptotechin in human prostate tumors, 71(8), 4431-4431.
- [15]. Guo L, Gao G, Liu X and Liu F. (2008). Preparation and charecterization of Tio2 nanosponges. *Materials Chemistry and Physics*, 111(2-3), 322-325.
- [16]. Lee CL, Wu CC, Chiou HP, Syu CM, Huang CH and Yang CC. (2011). Mesoporous platinum nanosponges as electrocatalysts for the oxygen reduction reaction in an acidic electrolyte. *International Journal of Hydrogen Energy*, 36(11), 6433-6440.
- [17]. Swaminathan S, Pastero L, Serpe L, Trotta F, Vavia P, Aquilano D, Trotta M, Zara G and Cavalli R. (2010). Cyclodextrin –based nanosponges encapsulating camptothecin: Physiochemical characterization, stability and cytotoxicity. *European Journal of Pharmaceutics and Biopharmaceutics*, 74 (2), 193-201.
- [18]. Ramnik S, Nitin B, Jyotsana M and Horemam SN. (2010). Characterization of cyclodextrins inclusion complexesA Review. *Journal of Pharmaceutical Sciences and Technology*, 2(3), 171-183
- [19]. Rajeswari C, Alka A, Javed A and Khar RK. (2005). Cyclodextrin in the drug delivery: an update review. *American Association of Pharmaceutical Scientists*, 6(2), E329-E357
- [20]. Selvamuthukumar S, Anandam S, Kannan K and Manavalan R. (2012). Nanosponge; A novel class of drug delivery system –review. *Journal of Pharmacy and Pharmaceutical sciences*, 15(1), 103-111] [18 Shastrulagari S and Samskruthi KP. (2015). Nanosponge: novel emerging drug delivery system- a review .*International Journal of Pharmaceutical Sciences and Research*,6(2), 1000-12
- [21]. Moura FC and Lago RM. (2009). Catalytic growth of carbon nanotubes and nanofibres on Vermiculite to produce floatable hydrophobic “Nanosponges” for oil spill remediation. *Applied Catalysis B*, 90(3-4), 436-40
- [22]. Sharma R., Roderick B., and Pathak K., Evaluation of kinetics and mechanism of drug release from Econazole nitrate Nanosponges loaded carbopol Hydrogel. *Indian J of Pharma Edu and research* , 2011 ,45(1):25-31.
- [23]. Embil K., and NachtS.,Themicrosponge delivery system atopical delivery system with reduced irritancy incorporating multiple triggering mechanisms for the releaseof actives. *J Microencapsule* ,1996, 13:575–88.
- [24]. Mishra M.K., Shikhri M., Sharma R., and GoojarM.P.,Optimization, formulation, development and characterization of Eudragit RS 100 loaded microsponges and subsequent colonic delivery. *Int J of Drug Discovery And herbal Research*, 2011, 1(1): 8-13.
- [25]. Martin A., Swarbrick J., and Cammarrata A., In: *Physical Pharmacy-Physical Chemical Principles in Pharmaceutical Sciences*, 2003, 3rd Ed. 1991: 527.
- [26]. Emanuele A., and Dinarvand R., Preparation, Characterization and Drug Release from Thermoresponsive Microspheres. *Int JPharm.*,1995, 237-42.
- [27]. Kilicarslan M., and Baykara T., The effect of the drug/polymer ratiioon the properties of Verapamil HCl loaded microspheres. *IntJPharm.*, 2003, 252:99–109.
- [28]. Barkai A., Pathak V., and BenitaS., Polyacrylate (Eudragit retard)microspheres for oral controlled release of nifedipine, Formulation design and process optimization. *Drug Dev Ind Pharm.*,1990, 16:2057-2075.
- [29]. WesterR.,Patel R.,NatchS.,Leyden J.,MelendresJ.,andMaibachH.,Controlled release of benzoyl peroxide from a porous microsphere polymeric system can reduce topical irritancy, *J. Am. Acad. Derm.*,1991,24:720-726.

- [30]. Amber V., Shailendra S., Swarnalatha S., Cyclodextrin based novel drug delivery systems. *J Incl Phenom Macrocycl Chem.*, 2008, 62:23-42.
- [31]. Rajeswari C., Alka A., Javed A., Khar R K., Cyclodextrins in drug delivery: an update review. *AAPS pharmSciTech*, 2005, 6(2):E329-E357.
- [32]. Ramnik S., Nitin B., Jyotsana M., Horemats., Characterization of Cyclodextrin Inclusion complexes –A Review. *J Pharm Sci Tech*, 2010 ,2(3):171-183.
- [33]. Maravajhala V., Papishetty S., Bandlapalli S., Nanotechnology in the development of drug delivery system, *International journal of pharmaceutical sciences & research*, 2012, Vol. 3, Issue 1, 84-96.
- [34]. Rao M. R., Bajaj A. N., Pardeshi A. A., Aghav S. S., Investigation of Nanoporous colloidal carrier for solubility enhancement of Cefpodoximeproxetil , *Journal of pharmacy research*, 2012, vol. 5, Issue 5, pp 2496-2499.
- [35]. Swaminathan S., Cavalli R., Trotta F., and Vavia P.R., Invitro release modulation and conformational stabilization of a model protein using swellablepolyamidoaminenanospoges of cyclodextrin. *J InclPhemonMacrocycl Chem.*, 2010 ,DOI10.1007/s10847-010-9765-9.
- [36]. Cavali R, Akhter AK, Bisazza A, Giustetto P and Trotta F. (2010). Nanosponge Formulations as oxygen Delivery systems. *International Journal of Pharmaceutics*, 402(1-20), 254-7.
- [37]. Moya –Ortega MD, Alvarez LC, Concherio A and Loftsson T. (2012). Cyclodextrin –based nanogels for pharmaceutical and biomedical applications. *International Journal of Pharmaceutics*, 428(1), 152-163.
- [38]. JAnsari KA, Vavia PR, Trotta F and Cavalli R. (2011). Cyclodextrin –based nanospoges for delivery of resveratrol: in vitro charecterisation, stability, cytotoxicity and permeation study. *AAPS PharmsciTech*, 12(1), 279-286.